Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer
Objective: To dissect the correlated hematologic markers that reflect the clinical outcome or treatment response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or carboplatin) and paclitaxel. Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian ca...
Main Authors: | Chueh-Yi Huang, Yuh-Cheng Yang, Kung-Liahng Wang, Tze-Chien Chen, Jen-Ruei Chen, Chia-Sui Weng, Hung-Ju Chien, Chih-Long Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Taiwanese Journal of Obstetrics & Gynecology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455916300390 |
Similar Items
-
Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023-07-01) -
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
by: Wu-yun Wang, et al.
Published: (2021-01-01) -
Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
by: Doo Yong Chung, et al.
Published: (2021-06-01) -
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
by: Mattea Reinisch, et al.
Published: (2023-06-01) -
The Safety of Chemotherapy for Ovarian Malignancy during Pregnancy
by: Naidong Xing, et al.
Published: (2022-12-01)